Korean J Med.
2005 Jul;69(1):61-68.
Efficacy and safety of Leukoup(R) (Filgrastim, rhG-CSF) for chemotherapy induced neutropenia in solid tumors : A randomized, multicenter, phase III comparison with Grasin(R)
- Affiliations
-
- 1Division of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykkang@amc.seoul.kr
- 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- 3Department of Medical Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
- 4Department of Internal Medicine, Gachon Medical School, Gil Medical Center, Inchon, Korea.
- 5Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
-
BACKGROUND: It is a well known fact that granulocyte colony-stimulating factor (G-CSF) can reduce the severity and duration of neutropenia after chemotherapy. The aim of this study was to evaluate the efficacy and safety of newly developed G-CSF, Leukoup(R) by comparing with those of already approved G-CSF, Grasin(R).
METHODS
This study was designed as a randomized, multicenter, open label, phase III trial. Both G-CSFs were subcutaneously injected at the dose of 50 g/m2 daily from 24 hours after the end of chemotherapy and continued for 10 days. The primary end point was the time for neutrophil recovery to 2,000/mm3.
RESULTS
A total of 222 patients were enrolled in this study (110 for Leukoup(R) arm, 112 for Grasin(R) arm), and 184 completed the study. The mean of the days for neutrophil recovery in Leukoup(R) arm was 16.5 days, and that of Grasin was 15.9 days; the difference between two groups was 0.67 days, and 95% confidence interval was 1.51~2.86 days. Although the difference in neutrophil recovery between the two groups is not significantly different and still within the usual non-inferiority margin (50% of difference between G-CSF group and no treatment group: 3.15 days), this study couldn't demonstrate the non-inferiority of Leukoup(R) to Grasin(R) by pre-defined noninferiority margin (30% of difference between G-CSF group and no treatment group: 1.89 days). The results of other assessment points, the incidence and severity of adverse events showed no difference between the two groups.
CONCLUSION
The present study showed that Leukoup(R) was effective and safe as good as Grasin(R) for the prevention of chemotherapy-induced neutropenia, although the noninferiority of Leukoup(R) to Grasin(R) could not be demonstrated by the predefined non-inferiority margin.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Ticlopidine-induced Neutropeina Treated with rhG-CSF
- Effect of Leukokine in Patients with Acute Leukemia Receiving Induction Chemotherapy
- Complete Remission Induced by Filgrastim (rhG-CSF) in the Case of Relapsed Acute Lymphoblastic Leukemia after Unrelated Cord Blood Transplantation
- Efficacy of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) and Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (rhGM-CSF) in Neutropenic Children with Malignancies
- The Effectiveness and Safety of DA-3030 ( rhG-CSF ) for Chemotherapy - induced Neutropenia: A Randomized Controlled Trial
